How could treatment practice change with cancer immunotherapy combinations in patients with HCC?
Friday 11 September 2020, 14.00–15.00 CET
As the first day of the ILCA 2020 Virtual Conference draws to a close, we hope you were able to join us for the Roche-sponsored Virtual Industry Partner Symposium, How could treatment practice change with cancer immunotherapy combinations in patients with HCC?
In this symposium, the esteemed panel provided an overview of the evolving treatment landscape for HCC and reviewed the most recent data for cancer immunotherapy combinations. They also provided expert insights on the safety profiles of these combinations and how they can be handled. This was followed by an in-depth discussion on making informed and tailored treatment decisions for patients, given the ongoing expansion of the HCC armamentarium.
The symposium concluded with an active discussion of a patient case and an engaging live Q&A session, which facilitated a multidisciplinary dialogue between the panel and attendees.
If you missed it, you can watch it on demand at your own convenience on the conference platform (available 24 hours after the session, for 12 months).
|14.00–14.02||Welcome and introductions||Peter Galle|
|14.02–14.10||Navigating the shifting treatment patterns for HCC||Jian Zhou|
|14.10–14.20||Understanding the latest efficacy data for unresectable HCC||Peter Galle|
|14.20–14.35||Discussing safety with cancer immunotherapy combinations||Bruno Sangro|
|14.35–14.45||Making the correct clinical decisions: what do we need to know?||Riccardo Lencioni|
|14.45–15.00||Reviewing a patient case: who are the right patients for cancer immunotherapy combinations?||All faculty|